This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Zacks Analyst Blog Highlights: Alibaba, UnitedHealth, Merck, PetroChina and 3M
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alibaba, UnitedHealth, Merck, PetroChina and 3M
Trump Picks 5 Coronavirus Vaccine Candidates Per NYT Report
by Kinjel Shah
The candidates belong to five companies, Moderna, AstraZeneca, J&J, Merck and Pfizer.
AstraZeneca Inks Deal to Develop RMP Inhibitors for Cancer
by Zacks Equity Research
AstraZeneca (AZN) signs an oncology agreement with Accent Therapeutics to develop novel therapies targeting RNA-modifying proteins for treating cancer.
Roche Tecentriq-Avastin Combo Gets FDA Nod for Liver Cancer
by Zacks Equity Research
FDA approves Roche's (RHHBY) sBLA seeking approval of the Tecentriq-Avastin combo to treat HCC patients who have not received prior systemic therapy.
Top Stock Reports for Alibaba, UnitedHealth & Merck
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group (BABA), UnitedHealth (UNH) and Merck (MRK).
Box, Ulta Beauty, Merck, Gilead and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Box, Ulta Beauty, Merck, Gilead and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day
3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus Immunity
by Benjamin Rains
Let's dive into three large-cap pharmaceutical and biotech stocks that appear set to grow during the pandemic-induced downturn and the eventual recovery...
Best-Performing ETFs of Last Week
by Sweta Killa
While the rally was broad-based, airline and banking industry led the way higher last week.
Novartis' (NVS) Breast Cancer Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Novartis (NVS) gets positive CHMP opinion for breast cancer drug, Piqray. The company also announces other pipeline updates.
The Zacks Analyst Blog Highlights: Merck, Glaxo, Roche, Sanofi and Bristol-Myers
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Glaxo, Roche, Sanofi and Bristol-Myers
5 Top Stocks Up 100%+ in May With More Room to Run
by Tirthankar Chakraborty
Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."
Merck (MRK) Shares Looking Ripe For A Buy
by Daniel Laboe
Merck (MRK) is a pharmaceutical powerhouse that has been under-appreciated amid this health crisis
FDA Okays Lilly's Alzheimer's Disease Diagnostic Agent Tauvid
by Zacks Equity Research
With the US regulatory agency's nod, Eli Lilly's (LLY) Tauvid became the first and the only approved radioactive diagnostic agent to image tau NFTs in the brain for effectively evaluating AD patients.
Buy Merck Stock On Vaccine Hopes
by Daniel Laboe
Analysts are estimating the vaccine could boost Merck's topline by anywhere between $2 to $5 billion
Pharma Stock Roundup: MRK, RHHBY Give Coronavirus Updates,SNY to Sell Stake in REGN
by Kinjel Shah
Merck (MRK), Glaxo (GSK) and Roche (RHHBY) make progress in coronavirus research efforts.
Why Is Merck (MRK) Down 4% Since Last Earnings Report?
by Zacks Equity Research
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bristol-Myers (BMY) Wins EC Approval for MS Drug Zeposia
by Zacks Equity Research
Bristol-Myers (BMY) gets EC nod for Zeposia for the treatment of adult patients with relapsing remitting multiple sclerosis.
S&P Reclaims 3,000 Mark: Go Long With These ETFs
by Sweta Killa
Wall Street is rallying this quarter with the S&P 500 reclaiming its 3,000 level.
Stock Market News for May 27, 2020
by Zacks Equity Research
The three major indexes closed in the green on Tuesday, as investors remained hopeful about coronavirus vaccine and that economies around the globe were recovering from the pandemic-driven lockdown over the past few months.
Race for Coronavirus Vaccine Heats Up: Biotech ETFs to Gain
by Sweta Killa
The COVID-19 pandemic has kept biotech players all over the world on their toes for a vaccine. This new opportunity has made the sector the most attractive one to investors.
Biotech ETF (BBC) Hits a New 52-Week High
by Sweta Killa
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
Merck Inks 3 Deals for Coronavirus Anti-infective & Vaccines
by Zacks Equity Research
Merck (MRK) to buy Themis, which is making a COVID-19 vaccine. It is also buying global rights to a private biotech's antiviral candidate, EIDD-2801, which is in early clinical studies to treat COVID-19.
Dow Touches 25,000 in More Than 2 Months: 4 Blue-Chip Picks
by Nalak Das
The blue-chip index's northbound journey began on Mar 24 and is continuing barring occasional fluctuations.
The Zacks Analyst Blog Highlights: Bristol-Myers, Roche, AstraZeneca, Merck and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers, Roche, AstraZeneca, Merck and Johnson & Johnson
S&P Set to Open Above 3000
by Jeremy Mullin
Bulls start the week trying to break the 200-day moving average.